EQS-News: CEVEC Pharmaceuticals GmbH / Key word(s): Agreement CEVEC Pharmaceuticals GmbH: ROKOTE Laboratories licenses CEVEC’s CAP® Ad Technology for vaccine manufacturing 20.09.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. ROKOTE Laboratories licen.
CEVEC Pharmaceuticals GmbH: ROKOTE Laboratories Licenses CEVEC s CAP(R) Ad Technology for Vaccine Manufacturing theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Finnish Researchers Introduce a Nasal COVID Vaccine labmanager.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from labmanager.com Daily Mail and Mail on Sunday newspapers.
New academic spin-out based in Finland introduces a nasal spray vaccine against COVID
Mar 8 2021
Rokote Laboratories Finland Ltd., a newly-founded academic spin-out based in Finland is working to develop and introduce to the markets a nasal spray vaccine against COVID. The vaccine is based on research carried out at the University of Helsinki and the University of Eastern Finland.
Image Credit: University of Eastern Finland
The vaccine uses gene transfer technology developed at the University of Eastern Finland by Academy Professor Seppo Ylä-Herttuala s research group, and the technology has already been successfully used in several clinical trials using gene therapy to treat cardiovascular diseases and cancer.